The gut microbiota and anticancer immunotherapy, Laurence Zitvogel -- The bidirectional communication between tumor cells and other components of the tumor microenvironment, Phil Sloan -- Resistance mechanisms in immune checkpoint inhibitors and radiotherapy and how to overcome this, Kirsten Lauber -- DNA repair mechanisms as a new target in head and neck cancer, Kevin Harrington -- How to standardize molecular profiling programs for routine patient care, Ingeborg Tinhofer -- Novel immune oncology targets beyond PD-1/PD-L1 in head and neck cancer, Christophe Le Tourneau -- Analytic methods to understand head and neck cancer evolution to guide therapeutic approaches, Ben O'Leary -- Clinical cases, Jean Pascal Machiels -- Updates from the European Head & Neck Society (EHNS), Wojciech Golusinski (President of EHNS) Section 2: Primary disease Piero Nicolai -- Sensitivity and specificity of extranodal extension in SCCHN: unlocking the strongest prognostic factor in head and neckcancer, Brian O'Sullivan -- From photon to proton: what's in it for head and neck cancer patients?, Volker Budach -- Lessons learned from RTOG 1016 and DE-ESCALaTE: what's next?, Hisham Mehanna.-Treatment intensification in LA-SCCHN: what are the options and for who?, Jan Vermorken -- Immune checkpoint inhibitors in the curative setting: preclinical and clinical data, Jean-Pascal Machiels -- Carcinoma of unknown primary: diagnostics and the potential of transoral surgery, René Leemans -- Clinical cases, Volker Budach -- Individualized therapy in 1-line R/M-SCCHN: what selection criteria should we use?, Petr Szturz -- Patterns of response to immune oncology drugs: how relevant are they in SCCHN?, Amanda Psyrri -- The role of radiotherapy in oligometastatic or oligoprogressive disease in R/M-SCCHN, Daan Nevens -- Updates from the EORTC Head and Neck Cancer Group (HNCG), Jean-Pascal Machiels (Chair of EORTC-HNCG) -- Real world evidence in head and neck cancer, Anil D'Cruz (UICC president -- Pathology driven treatment of skull base tumors, Piero Nicolai -- Modern day reconstruction of facial bones, Sat Parmar -- Targeting molecular/minimal residual disease using novel technologies and clinical trials design, Lillian Siu -- New developments in surgery for malignant salivary gland tumors, Jeroen Meulemans -- New systemic therapies in salivary gland cancer, Ethan Argiris. Exercise and nutrition interventions in head and neck cancer, Paolo Bossi -- Telehealth intervention in head and neck cancer patients: a promise?, Irma Verdonck-de Leeuw.